Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
Morphogenesis is a clinical stage cell/gene therapy company focusing on a platform of cancer immunomodulators that stimulate the immune system to recognize and kill tumor cells. These off-the-shelf nucleic acid immunomodulators employ the expression of a proprietary protein that evokes patient-specific tumor recognition and broad immune activation and leads to a systemic and sustained response against tumor cells of the type that expressed the protein. Importantly, this mechanism of action is cancer agnostic, and our clinical development program is, therefore, multi-pronged. We have completed a Phase 1 clinical trial for late stage cutaneous melanoma and are about to begin Phase 2. We have also begun Phase 1 trials for other skin cancers. Our intellectual property portfolio comprises over 30 issued/pending patents with exclusivity for 15+ years. Our fully integrated facility is designed to accommodate activities from product R&D through the manufacture of final products under cGMP.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Morphogenesis_2C_20Inc__3165c075.jpg)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
1995
Main Therapeutic Focus:
Oncology
Lead Product in Development:
IFx-Hu2.0: immunomodulator
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
![photo](/sites/default/files/hubb_images/2996/photos/user1.Lawman.a89736df.jpg)
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved